University of California San Diego-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:University of California San Diego - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013568
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:87
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
University of California San Diego (UCSD), a subsidiary of University of California, is a public research university that offers education and research with a portfolio of undergraduate, graduate, postdoctoral and professional schools. It offers courses in various fields including arts and humanities, biological sciences, physical sciences, engineering, management, international relations and pacific studies, medicine, oceanography, pharmacy and pharmaceutical sciences, and social sciences. It offers more than 100 undergraduate majors in six disciplinary areas; social sciences, engineering, biology, science/math, arts, humanities and special/undeclared. The university provides various courses through six undergraduate colleges, five academic divisions and five graduate and professional schools. It also offers research in the areas of neuroscience, nanoscience and climate science, and provides research funding opportunities. UCSD is headquartered in La Jolla, California, the US.

University of California San Diego – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
University of California San Diego, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
University of California San Diego, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
University of California San Diego, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
University of California San Diego, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
University of California San Diego, Medical Devices Deals, 2011 to YTD 2017 11
University of California San Diego, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
University of California San Diego, Pharmaceuticals & Healthcare, Deal Details 15
Asset Purchase 15
UC San Diego Health Acquires San Diego Cancer Center 15
Partnerships 16
Oxeia Biopharmaceuticals Enters Into Partnership Agreement with University of California San Diego School of Medicine 16
University of California San Diego School of Medicine Enters into Agreement with Janssen Pharma 17
Biomed Realty Trust Enters into Agreement with University of California San Diego 18
Galmed Pharma Enters into Agreement with University of California 19
Janssen Pharma Enters into Agreement with University of California, San Diego 20
AccentCare Forms Joint Venture With UC San Diego Health System 21
ChemDiv Enters into R&D Agreement with UCSD, MIPT and SatRx 22
University of California and San Diego School of Medicine Partners with UC San Diego Moores Cancer Center 23
Pfizer Announces Co-Development Agreement With University Of California, San Diego 24
Regulus Therapeutics Enters Into Collaboration With University of California 26
Licensing Agreements 27
Creative Medical Technologies Enters into Licensing Agreement with University of California, San Diego 27
Oncternal Therapeutics Enters into Licensing Agreement with University of California 28
Curtana Pharma Enters into Licensing Agreement with University of California San Diego 29
Abreos Biosciences Enter into License Agreement with University of California San 30
RetroSense Therapeutics Enters into Licensing Agreement with University of California San Diego 31
DesignMedix Enters into Licensing Agreement with University of California, San Diego 32
PsychoGenics Enters into Licensing Agreement with University of California, San Diego 33
Forge Therapeutics Enters into Licensing Agreement with University of California San Diego 34
PsychoGenics Enters into Licensing Agreement with University of California, San Diego School of Medicine for Transgenic Mouse Model of a-Synucleinopathies 35
PsychoGenics Enters into Licensing Agreement with University of California, San Diego School of Medicine 36
Batu Biologics Enters into Licensing Agreement with University of California, San Diego 37
PaxVax Enters into Licensing Agreement with University Of California, San Diego 38
SomPharma Enters into Licensing Agreement with University of California, San Diego 39
Solstice Biologics Enters Into Licensing Agreement With University of California, San Diego 40
Arytha Biosciences Enters into Licensing Agreement with University of California, San Diego 41
DevaCell Enters into Licensing Agreement with University of California, San Diego 42
Sanofi Pasteur Enters Into Licensing Agreement With University of California, San Diego 43
University of California San Diego – Key Competitors 44
University of California San Diego – Key Employees 45
University of California San Diego – Locations And Subsidiaries 46
Head Office 46
Other Locations & Subsidiaries 46
Recent Developments 48
Strategy And Business Planning 48
Feb 08, 2016: UC San Diego Launches New Nonalcoholic Fatty Liver Disease Research Center 48
Government and Public Interest 50
Oct 23, 2017: Penn Radiology Researcher Awarded $3.9 Million to Help Develop First Three-Dimensional Digital Atlas of Brain Cells 50
Oct 17, 2017: Pair of Discoveries Illuminate New Paths to Flu and Anthrax Treatments 51
Sep 27, 2017: Camino Pharma Co-founder Receives $10.8 Million Grant for Development of Potential Drug for Cocaine and Nicotine Addiction 53
Sep 13, 2017: Researchers develop new strategy to target KRAS mutant cancer 54
Jul 31, 2017: Organovo and UC San Diego Receive $1.7 Million Grant From National Institutes of Health to Study Liver Disease 55
Apr 21, 2017: Using CRISPR to Reverse Retinitis Pigmentosa and Restore Visual Function 56
Feb 07, 2017: Cystinosis Research Foundation Grants Support Scientific Studies on Cell Function, New Treatments and the Quest for a Cure 57
Dec 12, 2016: 3D Chemokine Receptor Study Opens Door to Finding New Anti-Inflammatory Drugs 59
Nov 18, 2016: New method helps identify antibiotics in mass spectrometry datasets 60
Nov 01, 2016: Researchers identify new drug target for gastrointestinal stromal tumors 62
Oct 17, 2016: FDA awards 21 grants to stimulate product development for rare diseases 63
Oct 04, 2016: Revolutionary Clinical Trial Initiative Focuses on Precision Medicine, Collaboration and Data Sharing to Transform Outcomes for All Pancreatic Cancer Patients 65
Sep 22, 2016: Kenneth Rainin Foundation Awards Over $3 Million to High-Risk, High Reward Inflammatory Bowel Disease Research Projects 67
Sep 09, 2016: Six-day Clinical Trial Finds Integrative Medicine Program Alters Blood Serum 69
Sep 05, 2016: Promising drug leads identified to combat heart disease 70
Jul 21, 2016: Researchers ID cancer gene-drug combinations ripe for precision medicine 72
Jun 23, 2016: TSRI Scientists Reveal Single-Neuron Gene Landscape of the Human Brain 73
Jun 06, 2016: Novel imaging model helps reveal new therapeutic target for pancreatic cancer 75
Feb 22, 2016: Newly discovered HIV genome modification may put a twist on vaccine and drug design 76
Feb 10, 2016: Alcohol Also Damages the Liver by Allowing Bacteria to Infiltrate 77
Feb 08, 2016: Engineers 3D-print a New Lifelike Liver Tissue for Drug Screening 78
Jan 22, 2016: Biologists Develop Method for Antibiotic Susceptibility Testing 79
Jan 12, 2016: New NIH awards will support development of therapeutic alternatives to traditional antibiotics 81
Product News 83
Oct 26, 2017: Vanderbilt leads international effort to develop universal flu vaccine 83
Aug 31, 2016: Takeda Launches Largest Pharmaceutical Company-Sponsored Global Observational Study of Its Kind in Multiple Myeloma 84
Apr 11, 2017: ‘Neuron-reading’ nanowires could accelerate development of drugs for neurological diseases 85
Other Significant Developments 86
Oct 26, 2017: The Human Vaccines Project Launches New Initiative To Accelerate Development Of Universally Effective Influenza Vaccines 86
Appendix 87
Methodology 87
About GlobalData 87
Contact Us 87
Disclaimer 87

List of Tables
University of California San Diego, Pharmaceuticals & Healthcare, Key Facts, 2015 2
University of California San Diego, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
University of California San Diego, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
University of California San Diego, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
University of California San Diego, Deals By Therapy Area, 2011 to YTD 2017 9
University of California San Diego, Medical Devices Deals, 2011 to YTD 2017 11
University of California San Diego, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
UC San Diego Health Acquires San Diego Cancer Center 15
Oxeia Biopharmaceuticals Enters Into Partnership Agreement with University of California San Diego School of Medicine 16
University of California San Diego School of Medicine Enters into Agreement with Janssen Pharma 17
Biomed Realty Trust Enters into Agreement with University of California San Diego 18
Galmed Pharma Enters into Agreement with University of California 19
Janssen Pharma Enters into Agreement with University of California, San Diego 20
AccentCare Forms Joint Venture With UC San Diego Health System 21
ChemDiv Enters into R&D Agreement with UCSD, MIPT and SatRx 22
University of California and San Diego School of Medicine Partners with UC San Diego Moores Cancer Center 23
Pfizer Announces Co-Development Agreement With University Of California, San Diego 24
Regulus Therapeutics Enters Into Collaboration With University of California 26
Creative Medical Technologies Enters into Licensing Agreement with University of California, San Diego 27
Oncternal Therapeutics Enters into Licensing Agreement with University of California 28
Curtana Pharma Enters into Licensing Agreement with University of California San Diego 29
Abreos Biosciences Enter into License Agreement with University of California San 30
RetroSense Therapeutics Enters into Licensing Agreement with University of California San Diego 31
DesignMedix Enters into Licensing Agreement with University of California, San Diego 32
PsychoGenics Enters into Licensing Agreement with University of California, San Diego 33
Forge Therapeutics Enters into Licensing Agreement with University of California San Diego 34
PsychoGenics Enters into Licensing Agreement with University of California, San Diego School of Medicine for Transgenic Mouse Model of a-Synucleinopathies 35
PsychoGenics Enters into Licensing Agreement with University of California, San Diego School of Medicine 36
Batu Biologics Enters into Licensing Agreement with University of California, San Diego 37
PaxVax Enters into Licensing Agreement with University Of California, San Diego 38
SomPharma Enters into Licensing Agreement with University of California, San Diego 39
Solstice Biologics Enters Into Licensing Agreement With University of California, San Diego 40
Arytha Biosciences Enters into Licensing Agreement with University of California, San Diego 41
DevaCell Enters into Licensing Agreement with University of California, San Diego 42
Sanofi Pasteur Enters Into Licensing Agreement With University of California, San Diego 43
University of California San Diego, Key Competitors 44
University of California San Diego, Key Employees 45
University of California San Diego, Subsidiaries 46

★海外企業調査レポート[University of California San Diego-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Cedar Fair, L.P.:企業の戦略・SWOT・財務情報
    Cedar Fair, L.P. - Strategy, SWOT and Corporate Finance Report Summary Cedar Fair, L.P. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Agios Pharmaceuticals Inc (AGIO):製薬・医療:M&Aディール及び事業提携情報
    Summary Agios Pharmaceuticals Inc (Agios) is a biopharmaceutical company that focuses on the discovery and development of investigational medicines for the treatment of cancer and rare genetic metabolic disorders. The company’s products include IDHIFA, an oral targeted inhibitor of the mutated IDH2 …
  • Energy Focus, Inc. (EFOI)-エネルギー分野:企業M&A・提携分析
    Summary Energy Focus, Inc. (Energy Focus) is a provider of energy efficient LED lighting products and technologies. The company, together with its subsidiaries, designs, develops, manufactures, markets, and installs energy-efficient lighting systems and solutions. Its military maritime products incl …
  • Covance Inc:企業の戦略的SWOT分析
    Covance Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Competitive Power Ventures Inc:企業の戦略的SWOT分析
    Competitive Power Ventures Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Parker Drilling Co (PKD):企業の財務・戦略的SWOT分析
    Parker Drilling Co (PKD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Advocate Health Care:製薬・医療:M&Aディール及び事業提携情報
    Summary Advocate Health Care (Advocate Health) is a nonprofit health system that provides health care services. It provides health care services such as inpatient acute and non-acute care, primary and specialty physician services and various outpatient services to communities in Illinois. The organi …
  • Pakistan Oxygen Limited (LINDE):企業の財務・戦略的SWOT分析
    Pakistan Oxygen Limited (LINDE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Gujarat State Electricity Corp Ltd:企業の戦略的SWOT分析
    Gujarat State Electricity Corp Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • SunOpta Inc.:企業の戦略・SWOT・財務情報
    SunOpta Inc. - Strategy, SWOT and Corporate Finance Report Summary SunOpta Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Nascent Biotech Inc (NBIO):製薬・医療:M&Aディール及び事業提携情報
    Summary Nascent Biotech Inc (Nascent) is a clinical-stage biopharmaceutical company. The company delivers human monoclonal antibodies and cytokine for the treatment of cancer and drug discovery platform for identifying new antibodies and antigens for commercialization. It develops Pritumumab, a mono …
  • Genmedica Therapeutics SL-製薬・医療分野:企業M&A・提携分析
    Summary Genmedica Therapeutics SL (Genmedica) is a clinical-stage biopharmaceutical company that researches, discovers and develops orally available NCEs for the treatment of diabetes. The company’s expertise spans in the development of specific, dual-action, small molecule inhibitors that targets b …
  • Taisho Pharmaceutical Holdings Co Ltd:戦略・SWOT・企業財務分析
    Taisho Pharmaceutical Holdings Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Taisho Pharmaceutical Holdings Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Neiman Marcus Group Ltd. LLC:企業の戦略的SWOT分析
    Neiman Marcus Group Ltd. LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • The Saudi Arabian Monetary Agency:企業の戦略的SWOT分析
    The Saudi Arabian Monetary Agency - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Arthur J. Gallagher & Co:企業のM&A・事業提携・投資動向
    Arthur J. Gallagher & Co - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Arthur J. Gallagher & Co Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • Varian Medical Systems, Inc.:戦略・SWOT・企業財務分析
    Varian Medical Systems, Inc. - Strategy, SWOT and Corporate Finance Report Summary Varian Medical Systems, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Electricity Generating Authority of Thailand:発電所・企業SWOT分析
    Electricity Generating Authority of Thailand - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, inf …
  • Green Plains Inc (GPRE):企業の財務・戦略的SWOT分析
    Green Plains Inc (GPRE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Korn Ferry (KFY):企業の財務・戦略的SWOT分析
    Korn Ferry (KFY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆